These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 35882670)

  • 21. Osteonecrosis of the Jaw and Antiresorptive Agents in Benign and Malignant Diseases: A Critical Review Organized by the ECTS.
    Anastasilakis AD; Pepe J; Napoli N; Palermo A; Magopoulos C; Khan AA; Zillikens MC; Body JJ
    J Clin Endocrinol Metab; 2022 Apr; 107(5):1441-1460. PubMed ID: 34922381
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Medication-related osteonecrosis of the jaw in oncological patients with skeletal metastases: conservative treatment is effective up to stage 2.
    Coropciuc RG; Grisar K; Aerden T; Schol M; Schoenaers J; Politis C
    Br J Oral Maxillofac Surg; 2017 Oct; 55(8):787-792. PubMed ID: 28760314
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Osteonecrosis of the jaw among patients with cancer treated with denosumab or zoledronic acid: Results of a regulator-mandated cohort postauthorization safety study in Denmark, Norway, and Sweden.
    Ehrenstein V; Heide-Jørgensen U; Schiødt M; Akre O; Herlofson BB; Hansen S; Larsson Wexell C; Nørholt SE; Tretli S; Kjellman A; Glennane A; Lowe KA; Sørensen HT
    Cancer; 2021 Nov; 127(21):4050-4058. PubMed ID: 34310704
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and efficacy of bone-modifying agents among multiple myeloma patients: A retrospective cohort study.
    Billias C; Langer M; Ursu S; Schorr R
    J Oncol Pharm Pract; 2022 Apr; 28(3):523-529. PubMed ID: 33593137
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The status of jaw lesions and medication-related osteonecrosis of jaw in patients with multiple myeloma.
    Lu SY; Ma MC; Wang MC; Hsue SS
    J Formos Med Assoc; 2021 Nov; 120(11):1967-1976. PubMed ID: 33551311
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Emerging therapies with potential risks of medicine-related osteonecrosis of the jaw: a review of the literature.
    Kanwar N; Bakr MM; Meer M; Siddiqi A
    Br Dent J; 2020 Jun; 228(11):886-892. PubMed ID: 32541753
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Medication-related osteonecrosis of the jaw: risk factors in patients under biphosphonate versus patients under antiresorptive-antiangiogenic drugs.
    Ghidini G; Manfredi M; Giovannacci I; Mergoni G; Sarraj A; Mureddu M; Giunta G; Bonanini M; Meleti M; Vescovi P
    Minerva Stomatol; 2017 Aug; 66(4):135-140. PubMed ID: 28497661
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Incidence of and risk factors for medication-related osteonecrosis of the jaw in women with breast cancer with bone metastasis: a population-based study.
    Hallmer F; Bjarnadottir O; Götrick B; Malmström P; Andersson G
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2020 Sep; 130(3):252-257. PubMed ID: 32536575
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Does medication-related osteonecrosis of the jaw affect survival of patients with Multiple Myeloma?: Exploring a large single center database using artificial intelligence.
    Bittrich M; Hetterich R; Solimando AG; Krebs M; Loda S; Danhof S; Anton S; Zhou X; Kerscher A; Beilhack A; Kortüm KM; Rasche L; Einsele H; Knop S; Hartmann S
    Clin Exp Med; 2023 Dec; 23(8):5215-5226. PubMed ID: 37805620
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clarithromycin as the empiric antibiotic therapy for medication-related osteonecrosis of the jaw in multiple myeloma patients.
    Zadik Y
    Oral Oncol; 2018 Sep; 84():104-105. PubMed ID: 30115467
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Incidence of osteonecrosis of the jaw by the use of osteoclast inhibitors in patients with bone metastases: a retrospective cohort study.
    Chaurand-Lara J; Pacheco-Ruiz L; Trejo-Campos JL; Facio-Umaña JA; Mora-Pérez J
    Cir Cir; 2019; 87(4):396-401. PubMed ID: 31264983
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A 5-year retrospective longitudinal study on the incidence and the risk factors of osteonecrosis of the jaws in patients treated with zoledronic acid for bone metastases from solid tumors.
    Manfredi M; Mergoni G; Goldoni M; Salvagni S; Merigo E; Meleti M; Vescovi P
    Med Oral Patol Oral Cir Bucal; 2017 May; 22(3):e342-e348. PubMed ID: 28390132
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Medication-related osteonecrosis of the jaw (MRONJ) and eNOS Polymorphisms in multiple myeloma patients: a single center experience.
    Taş Ozyurtseven B; Serin I; Nursal AF; Pehlivan S; Pehlivan M
    BMC Oral Health; 2021 May; 21(1):272. PubMed ID: 34006261
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Medication-related osteonecrosis of the jaw: Prevention, diagnosis and management in patients with cancer and bone metastases.
    Otto S; Pautke C; Van den Wyngaert T; Niepel D; Schiødt M
    Cancer Treat Rev; 2018 Sep; 69():177-187. PubMed ID: 30055439
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mesenchymal stromal cells administration for osteonecrosis of the jaw caused by bisphosphonate: report of two cases.
    De Santis GC; de Macedo LD; Orellana MD; Innocentini LMAR; Ferrari TC; Ricz HMA; Caruso SR; Fernandes TR; Covas DT
    Acta Oncol; 2020 Jul; 59(7):789-792. PubMed ID: 32079438
    [No Abstract]   [Full Text] [Related]  

  • 36. Risk factors for developing osteonecrosis of jaw in advanced cancer patients underwent zoledronic acid treatment.
    Qi WX; Zhao S; Chen J
    Future Oncol; 2019 Oct; 15(30):3503-3511. PubMed ID: 31580147
    [No Abstract]   [Full Text] [Related]  

  • 37. Osteonecrosis of the jaws: a 14-year retrospective survey of hospital admissions.
    McGowan K; Ivanovski S; Acton C
    Aust Dent J; 2018 Jun; 63(2):202-207. PubMed ID: 29432652
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Thirteen cases of jaw osteonecrosis in patients on bisphosphonate therapy.
    Vieillard MH; Maes JM; Penel G; Facon T; Magro L; Bonneterre J; Cortet B
    Joint Bone Spine; 2008 Jan; 75(1):34-40. PubMed ID: 17981488
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Medication-related osteonecrosis of the jaw after once-a-year intravenous zoledronic acid infusion for osteoporosis: Report of eight cases.
    Favia G; Tempesta A; Limongelli L; Crincoli V; Maiorano E
    Quintessence Int; 2016; 47(5):433-40. PubMed ID: 26665262
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of Radium-223 Dichloride in Patients With Osteonecrosis of the Jaw Induced by Zoledronic Acid: Report of 2 Cases.
    Dionisi V; Bellarosa C; Cardano R; Rizzini EL; Ghedini P; Morganti AG; Fanti S; Monari F
    Clin Genitourin Cancer; 2019 Jun; 17(3):e612-e617. PubMed ID: 30956096
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.